The acting chair of the, Mark Uyeda, took the first step Tuesday to rolling back a rule that would require thousands of ...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of ...

CSL’s balance sheet is in sound condition. Financial risk is low given low revenue cyclicality and product demand is being largely driven by chronic indications. We forecast CSL’s net debt to EBITDA ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

DuPont de Nemours raised its 2025 profit forecast and beat fourth-quarter earnings estimates on Tuesday, as the industrial ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...

The Boston Globe reports that the layoff is the largest in the organization’s history and comes amid financial shortfalls and operational challenges. Also in industry and pharma news: the nurse strike ...